GleamWall
中文EN

STOK Stoke Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1623526 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-86.3%
TTM net income YoY-699.5%
TTM EPS YoY-655.9%
Revenue 3-yr CAGR45.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-913.1%
Net margin-862.1%
FCF margin-764.7%
EBITDA margin-906.9%

Returns

ROE-73.6%
ROA-63.4%
ROIC (approx.)-86.6%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets13.3%
Debt / equity0.00x
Current ratio7.24x
Interest coverage-4,088.90x

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-8.6%
Payout ratio—
Capex / revenue19.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$11.26M$9.32M$6.23M$1.40M$10.63M$13.82M$158.57M$22.61M
R&D expense$59.83M$49.50M$39.67M$41.70M$37.70M$25.86M$32.68M$23.42M
SG&A expense$28.74M$25.25M$19.97M$21.15M$16.03M$15.26M$14.65M$12.84M
Operating income-$77.31M-$65.43M-$53.42M-$61.44M-$43.09M-$27.30M$111.24M-$13.65M
Interest expense$20,000$17,000$23,000$3,000$3,000$3,000$1,000-$1,000
Pretax income-$73.64M-$61.62M-$50.00M—-$39.62M-$23.48M$114.16M—
Income tax$0$0$0$0-$1.28M$0$1.28M—
Net income-$73.64M-$61.62M-$50.00M-$57.93M-$38.35M-$23.48M$112.88M-$10.48M
EBITDA-$76.86M-$64.97M-$52.98M-$61.03M-$42.65M-$26.85M$111.72M-$13.13M
EPS (basic)-1.08-0.93-0.79—-0.65-0.401.95—
EPS (diluted)-1.08-0.93-0.79—-0.65-0.401.90—
Weighted avg. shares (diluted)68.36M66.02M63.06M—58.61M58.35M59.40M—
Balance sheet
Cash & equivalents$107.27M$110.00M$155.66M$84.22M$83.39M$101.47M$274.82M$127.98M
Short-term investments$211.92M$182.81M$187.89M$200.45M$164.92M$146.24M$82.51M$88.92M
Receivables$8.54M$7.18M$4.45M$5.94M$9.25M——$1.67M
Current assets$354.42M$322.54M$366.68M$305.70M$272.44M$269.97M$375.74M$232.76M
PP&E, net$8.21M$4.83M$3.40M$3.15M$3.08M$3.34M$3.61M$3.91M
Total assets$406.69M$393.97M$443.28M$418.43M$360.26M$384.51M$406.89M$271.56M
Current liabilities$48.98M$41.93M$40.81M$57.88M$41.73M$38.68M$44.69M$40.06M
Total liabilities$54.10M$48.42M$48.40M$65.98M$52.16M$49.56M$56.81M$42.53M
Shareholders' equity$352.59M$345.55M$394.88M$352.46M$308.11M$334.94M$350.07M$229.02M
Shares outstanding64.81M62.40M62.24M58.92M55.12M54.72M54.60M54.03M
Cash flow statement
Operating cash flow-$62.69M-$56.59M-$60.58M-$30.45M-$30.37M-$25.42M$131.83M-$23.19M
Capital expenditure$2.85M$1.98M$353,000$232,000$132,000$154,000$152,000$42,000
Free cash flow-$65.54M-$58.56M-$60.94M-$30.69M-$30.50M-$25.58M$131.68M-$23.23M
Investing cash flow-$10.21M$9.02M$50.69M-$61.06M$9.09M-$148.48M$13.63M$819,000
Financing cash flow$70.16M$1.91M$84.33M$92.34M$3.12M$554,000$1.37M$568,000
Depreciation & amortization$455,000$458,000$439,000$405,000$442,000$446,000$477,000$526,000
Stock-based compensation$11.03M$10.80M$8.75M$9.85M$8.04M$7.60M$6.75M$7.14M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.